Back

Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial

Li, J. H.; Szczerbinski, L.; Tripputi, M.; Liu, H.; Nam, S.; Mujica, E.; Emmanouilidou, A.; Wangden, T. Y.; Citko-Rojewska, A.; Konopka, P.; Czajkowski, M.; Huerta-Chagoya, A.; Vora, M.; Leong, A.; Meigs, J. B.; Ng, M. Y.; Loos, R. J. F.; Pigeyre, M.; Gerstein, H. C.; Moura, F. A.; Lai, Y.-P.; Bhatt, D. L.; Marston, N. A.; Ruff, C. T.; Sabatine, M. S.; Dawed, A. Y.; Pearson, E. R.; Satin, L. S.; den Hoed, M.; Kretowski, A.; Kahn, S. E.; Younes, N.; Mercader, J. M.; Florez, J. C.; GRADE Research Group,

2025-10-08 genetic and genomic medicine
10.1101/2025.10.07.25336827 medRxiv
Show abstract

Optimizing second-line therapy for type 2 diabetes is challenging due to interindividual variability in response. We conducted a pharmacogenomic genome-wide association study (GWAS) in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin, when added to metformin in a diverse population. We identified 21 genome-wide significant loci associated with treatment response. rs1905505, a non-coding variant near SLC2A2, the gene encoding the glucose transporter GLUT2, was enriched in Africans/African Americans and conferred a 36% increased risk of treatment failure on glimepiride (p=4.83x10). Carriers had impaired {beta}-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to an acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuates the glucose-lowering effect of glimepiride. In conclusion, genetic variation influences glycemic response to medications, with SLC2A2 emerging as a key determinant of sulfonylurea response. Clinical Trial registration number: NCT01794143

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.